Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
| Market Cap | 8.69B |
| Revenue (ttm) | 189.53M |
| Net Income (ttm) | -888.51M |
| Shares Out | 65.11M |
| EPS (ttm) | -14.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,287 |
| Open | 131.37 |
| Previous Close | 131.58 |
| Day's Range | 131.05 - 135.40 |
| 52-Week Range | 62.57 - 151.51 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 150.82 (+11.5%) |
| Est. Earnings Date | Nov 8, 2021 |
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indi...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is 150.82, which is an increase of 11.55% from the latest price.
News
Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations
Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For ...
NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-sta...
Why Are Biohaven Shares Trading Lower On Monday?
Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA). Verdiperstat did not diffe...
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treat...
NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More
With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021.
Biohaven Pharma: Q2 Earnings Insights
Shares of Biohaven Pharma Hldgs (NYSE:BHVN) rose 0.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 2.75% year over year to ($2.62), which b...
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look O...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race
NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec® ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix.
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202
NEW HAVEN, Conn., July 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Will This Biopharma Company Continue to Crush It?
Migraine sufferers certainly hope so.
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations
Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.
Here's Why Biohaven Pharmaceutical Is Soaring Today
Preliminary sales figures for the company's new migraine drug were much better than expected.
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For ...
NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 ...
Biohaven Appoints Kishen Mehta to Board of Directors
NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimeg...
New Strong Sell Stocks for June 14th
CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.